Hydroxychloroquine After Complete Heart Block Diagnosis and Relationship to Patient Outcomes: A Descriptive Cohort Study
Prenatal Diagnosis · 2026
DOI: 10.1002/pd.70036 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Prenatal Diagnosis, 2026. Verfasst von Elizabeth L Carter und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Hydroxychloroquine, Heart Block. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Objective
Congenital complete heart block (CHB) carries significant morbidity and mortality. Maternal Hydroxychloroquine may prevent CHB in subsequent pregnancies. No studies have explored the benefit of Hydroxychloroquine initiated after the diagnosis of CHB. We hypothesized fetuses exposed to Hydroxychloroquine, even after CHB diagnosis, will have improved outcomes using time to pacemaker placement as the primary outcome.
Methods
A single‐center retrospective study was conducted on patients with CHB secondary to maternal anti‐SSA antibodies approximately 2005–2024.
Results
All patients ( n = 42) received prenatal Dexamethasone. Twenty‐four patients received prenatal Dexamethasone + Hydroxychloroquine; nine were started on Hydroxychloroquine prior to CHB diagnosis, while 15 were started on Hydroxychloroquine after diagnosis. Fetal hydrops occurred more in patients treated with Dexamethasone alone ( p = 0.004). Oligohydramnios occurred more in patients on Dexamethasone + Hydroxychloroquine ( p = 0.003). There was a higher likelihood of pacing at birth in the Dexamethasone only group ( p = 0.045), but no further significant differences in timing to pacemaker placement. Long‐term survival was similar.
Conclusion
Increased rates of hydrops fetalis and the need for pacing at birth in the Dexamethasone only group suggest a possible positive effect of Hydroxychloroquine in utero, even if administered after the diagnosis of CHB. This study is limited by the small sample size and the inability to control for covariates. Further multicenter studies would help explore whether adjunctive treatment with Hydroxychloroquine improves outcomes, even when initiated after CHB diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Division of Pediatric General Thoracic and Fetal Surgery, Richard D. Wood, Jr. Center for Fetal Diagnosis and Treatment, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Elizabeth L Carter, Juliana Gebb
Zitieren
APA
Carter, E. L., Gebb, J., Janson, C., & Szwast, A. (2026). Hydroxychloroquine After Complete Heart Block Diagnosis and Relationship to Patient Outcomes: A Descriptive Cohort Study. Prenatal Diagnosis. https://doi.org/10.1002/pd.70036
Vancouver
Carter EL, Gebb J, Janson C, Szwast A. Hydroxychloroquine After Complete Heart Block Diagnosis and Relationship to Patient Outcomes: A Descriptive Cohort Study. Prenatal Diagnosis. 2026. doi:10.1002/pd.70036
BibTeX
@article{Carter2026,
author = {Carter, Elizabeth L and Gebb, Juliana and Janson, Christopher and Szwast, Anita},
title = {Hydroxychloroquine After Complete Heart Block Diagnosis and Relationship to Patient Outcomes: A Descriptive Cohort Study},
journal = {Prenatal Diagnosis},
year = {2026},
doi = {10.1002/pd.70036}
}
EUVIMED